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Effective population screening for glaucoma would enable earlier diagnosis and prevention of irreversible vision loss. The UK
National Screening Committee (NSC) recently published a review that examined the viability, effectiveness and appropriateness of a
population-based screening programme for primary open-angle glaucoma (POAG). In our article, we summarise the results of the
review and discuss some future directions that may enable effective population screening for glaucoma in the future. Two key
questions were addressed by the UK NSC review; is there a valid, accurate screening test for POAG, and does evidence exist that
screening reduces morbidity from POAG compared with standard care. Six new studies were identified since the previous 2015
review. The review concluded that screening for glaucoma in adults is not recommended because there is no clear evidence for a
sufficiently accurate screening test or for better outcomes with screening compared to current care. The next UK NSC review is due
to be conducted in 2023. One challenge for POAG screening is that the relatively low disease prevalence results in too many false-
positive referrals, even with an accurate test. In the future, targeted screening of a population subset with a higher prevalence of
glaucoma may be effective. Recent developments in POAG polygenic risk prediction and deep learning image analysis offer
potential avenues to identifying glaucoma-enriched sub-populations. Until such time, opportunistic case finding through General
Ophthalmic Services remains the primary route for identification of glaucoma in the UK and greater public awareness of the service
would be of benefit.
Eye; https://doi.org/10.1038/s41433-021-01687-8
INTRODUCTION
Glaucoma is the second most common cause of blindness globally
[1]. Unlike cataract, the leading cause of blindness, glaucoma
causes irreparable vision loss. This, in combination with the
progressive nature of the disease, means that early detection and
treatment are critical for preventing blindness from glaucoma [2].
The asymptomatic nature of mild glaucoma means that examina-
tion is required for early detection [2]. While the necessity for early
diagnosis to prevent blindness may suggest that glaucoma is a
good candidate for population screening, inadequate tests for the
relatively low prevalence in the population have so far precluded a
national screening programme. Currently in the UK, glaucoma
detection is opportunistic, most frequently by optometrist
assessment in the community. A recent population-based study
in Northern Ireland suggests that the majority of people with
glaucoma are undetected or are at least unaware of their
diagnosis [3].
The UK National Screening Committee (UK NSC) regularly
reviews the evidence supporting population screening to provide
recommendations to the government and National Health Service
(NHS) in the UK. In 2019, the UK NSC updated their 2015 review of
available evidence supporting population screening for the
commonest form of glaucoma, primary open-angle glaucoma
(POAG) [4]. The 2019 report states that the UK NSC still cannot
recommend population screening for POAG in adults due to
inadequate supporting evidence. In this article, we present a
summary of the findings of the 2019 UK NSC review and discuss
potential future directions that may enable effective population
screening of POAG.
UK NATIONAL SCREENING COMMITTEE EXTERNAL REVIEW OF
SCREENING FOR GLAUCOMA, 2019
Aims
The viability, effectiveness and appropriateness of a population-
based screening programme for POAG were assessed by the UK
National Screening Committee (UK NSC) and their review was
published in December 2019 [4]. Two key questions relating to the
UK NSC screening criteria were evaluated to determine whether
there was any new relevant evidence published since the last
review in March 2015 and therefore whether to reconsider the
recommendation of the last review against population screening
for POAG in the UK. These two questions considered firstly
whether there is a valid, accurate screening test for POAG and
secondly whether evidence exists that POAG screening reduces
morbidity from the condition compared with standard diagnosis
and care. The NSC commissioned the evidence review which was
carried out using rapid review methodologies [5].
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Methods
A systematic search of three databases (Medline, Embase and
Cochrane) was undertaken to identify relevant studies published
since 1 October 2014 up to 25 March 2019 in relation to the key
questions; search criteria are summarised in Table 1.
Findings: is there a good screening test for POAG?
The review initially searched for information on the diagnostic
accuracy of screening tests for POAG in the adult population to
assess whether there is a simple, safe, precise, and validated
screening test. When this question was assessed by the UK NSC
review in 2015, one meta-analysis, one systematic review, six
studies assessing functional tests and two studies assessing
structural tests were analysed. Overall, the studies had small
sample sizes and a wide variability in the sensitivity and specificity
of the available tests were reported, deeming them unsuitable for
use in population screening.
In the 2019 review, six new studies [6–11] met the inclusion
criteria after full-text review (Tables 2 and 3). The studies reported
POAG screening test performance results in populations with
unknown ocular history; sample sizes ranged from 220 [9] to 4167
[7]. Five of the studies targeted people with a higher risk of
developing POAG due to ethnicity, age, or family history [6, 8–11].
All studies used combinations of functional and structural types of
screening test and employed a screening algorithm or model to
determine who should be referred for a definitive eye examination
(the reference standard). The results of the definitive eye
examination were typically ‘no glaucoma’, ‘suspected glaucoma’
or ‘definitive glaucoma’. The studies combined the tests used at
the screening examination to calculate screening performance
statistics. No studies combined the same screening tests with the
same cut-offs. The reported performance of individual and
combined screening tests from these studies are summarised in
Tables 2 and 3, respectively.
There was no agreement about the most effective combination
of tests or cut-off levels that should be used in a screening
examination for POAG. The screening test performance statistics
reported were variable and not comparable across studies. The
review concluded that there is an insufficient evidence base for a
simple, safe, precise and validated screening test with known
distribution of test values and agreed suitable cut-off levels.
Findings: does screening for POAG reduce morbidity?
The review subsequently searched for studies that investigated
whether a screening programme for POAG was effective in
reducing the morbidity associated with the condition. The March
2015 review assessed four studies [12–15], all of which concluded
that there was insufficient evidence to recommend population-
based screening for POAG. Burr et al. also reported that glaucoma
screening of a population selected on age is unlikely to be cost-
effective and that there is uncertainty surrounding test perfor-
mance as well as around engagement with a POAG screening
programme [15]. The 2013 US Preventative Services Task Force
recommendation statement reported concerns about overdiag-
nosis and possible overtreatment as not all people go on to
develop visual impairment [14]. Ervin et al. did not identify any
studies to provide evidence for links between whether glaucoma
screening impacted on visual field loss, visual impairment,
optic nerve damage, intraocular pressure or patient-reported
outcomes [13].
In the 2019 review, three additional studies reporting results of
screening programmes were identified [8, 11, 16]. However, none
of the studies reported any data regarding treatment outcomes or
overall outcomes of the whole-screening programme perfor-
mance. Anton et al. performed a cross-sectional study and
reported detection rates (4.1% of those screened had glaucoma
or suspect glaucoma) and costs of a screening programme (1410 €

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































population in Spain [16]. The screening performance statistics
were beyond the scope of the study and the treatment outcomes
and overall screening programme performance were not
reported. A study by Hark et al. examined the agreement of
ocular findings between telemedicine eye screening comprising
fundus photography, tonometry, and clinical information, with
diagnosis made from a comprehensive eye examination in an
at risk population in Philadelphia [11]. They reported 29.2%
detection rate of glaucoma-related eye disease (glaucoma,
glaucoma suspect and narrow angle) in those screened; the
diagnosis confirmation rate was 80% after eye examination.
Performance statistics were not reported. Zhao et al. focussed on
the accuracy of screening tests in the development of a screening
programme in an at-risk population in Baltimore, but did not
report performance statistics [8].
The UK NSC review did not identify any randomised controlled
trials examining the effectiveness of a POAG screening pro-
gramme in reducing disease morbidity from the condition
compared with usual diagnosis and care.
Conclusion and recommendations
Following this assessment, the committee concluded that none of
the existing screening protocols should be recommended for
POAG in adults. This is in line with the previous UK NSC
recommendation from 2015. It is also in agreement with the
2017 National Institute for Health and Care Excellence (NICE)
glaucoma guideline [17] which assessed the accuracy of five risk
tools to predict conversion to POAG in people with ocular
hypertension; the report concluded that the current evidence on
the sensitivity and specificity of risk tools for developing POAG is
of moderate to low quality, with all studies having a high or very
high risk of bias [17]. The next UK NSC review is due to be
conducted in 2022/23.
Limitations
Although the evidence review underpinning the UK NSC
recommendation has potential minor limitations such as search-
ing only three electronic databases and not the grey literature,
the main limitation is insufficient evidence to judge whether
population screening for glaucoma is worthwhile in terms of a
suitable screening test and whether the benefits of a glaucoma
screening programme outweigh any potential harms. Ideally,
before instigating any screening programme evidence of
effectiveness from a randomised controlled screening trial is
required. However, conducting such as trial of glaucoma
screening is unlikely to be the best use of research resources
[15] until some fundamental questions regarding what any
future glaucoma screening programme is trying to achieve are
addressed. In particular, the target population, the type and
severity of glaucoma one is trying to detect and underlying
consensus definitions.
FUTURE DIRECTIONS
One of the challenges to effective population screening for
glaucoma is the relatively low disease prevalence in the general
population combined with the reasonable performance of
opportunistic case finding. A low disease prevalence results in a
poor positive predictive value of even very accurate tests (see
below). While screening for glaucoma in younger compared to
older people is more likely to be beneficial in terms of reducing
glaucoma disability, the prevalence of POAG in the general
population selected on age alone, even in older age cohorts, is too
low for a population-based screening programme to be recom-
mended. Such a programme would overburden health services.
For example, if we assume the prevalence of glaucoma in an
inception cohort aged 50 years to be 0.9% [18], and the
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sensitivity and 96% specificity [19], the positive predictive value
will be relatively poor (Fig. 1). In this scenario, a positive test that
will result in referral will be a false positive 86% of the time. In
other words, more than 8 out of 10 referrals will be unnecessary,
generating wasteful burden on secondary care services. Over-
burdened secondary eye care services have been highlighted as a
major problem and a cause of delays to the care of high-risk
patients [20, 21]. Therefore, an efficient screening programme is
required to have a higher positive predictive value (i.e., lower false
positive referral rate). This may be achieved either by targeted
testing of higher risk subgroups rather than inviting people
selected on age alone. Modelling suggests that initiating a
screening programme for a high-risk subset of a cohort aged 50
years, with an expected prevalence of POAG of around 4–5%
(rather than the 0.9% in the general population aged 50 years),
might be worthwhile [15, 18]. However, the systematic identifica-
tion of higher glaucoma risk subgroups in the population is
challenging.
One strategy could be targeting screening to families of people
with POAG. First-degree relatives of glaucoma patients have been
shown to have a ninefold increased risk of developing glaucoma
in their lifetime compared to relatives of controls in the
population-based Rotterdam Study [22]. The higher prevalence
of glaucoma in first-degree relatives will improve the positive
predictive value of any test, thereby reducing false-positive
referrals. While a formal screening programme targeting first-
degree relatives of glaucoma sufferers makes theoretical sense,
the practical application may not be straightforward. For example,
there would need to be a clear definition of which glaucoma
patients should have their relatives screened (e.g., POAG only or
other types of glaucoma as well) and these individuals would
need to be accurately identified at scale nationally. Self-report of
disease status is unreliable for glaucoma overall, and would likely
be worse for specific sub-types of glaucoma. In the future,
increasing uptake of electronic medical records may enable a
digital national glaucoma registry which could inform targeted
screening of first-degree relatives. However, many challenges
would persist including the practicality and ethical and informa-
tion governance implications of sharing health information or
linkage of health records with relatives.
In recent years, there has been great progress in the discovery
of the genetic determinants of POAG [23]. Over 100 common
genetic variants have been identified which each contribute a
small increased risk of high intraocular pressure (IOP) or POAG
[24]. When combined together, these variants cumulatively can
predict who will develop POAG with an area under the ROC curve
of 76% [24]. Further adding genetic variants which are associated
with vertical cup-disc ratio and glaucoma and creating a polygenic
risk score (PRS) for POAG has also demonstrated potential for
identifying individuals in a population who are at high risk for
disease [25]. In the Australia and New Zealand Registry of
Advanced Glaucoma (comprising 3071 advanced POAG cases
and 6750 historic controls of European descent), participants in
the top decile of PRS were at a 15-fold increased risk of
developing advanced glaucoma compared to the bottom decile
[25]. Compared to the remaining 90% of the cohort, participants in
the top decile of PRS were at a 4.2-fold increased risk of advanced
glaucoma.
If genetic data were available for the general population, we
would be able to target a glaucoma screening programme to
individuals at the highest genetic risk of developing advanced
glaucoma. If we apply the 4.2-fold increased risk in the top 10% to
the 50-year-old inception cohort, we would predict a glaucoma
risk of around 4%. If we were then to target screening to this
enriched sub-population with the aforementioned screening test
(73% sensitivity and 96% specificity), the false-positive rate would
Table 3. Combined screening test performance for suspected and definitive POAG.
Study Screening test combination Performance reported
Sensitivity % Specificity % Positive predictive value
Song et al.
[9]
CDR ratio (cut-offs ranged from >0.5
to >0.65), CDR difference between
eyes (≥0.2), RNFL defect and IOP
( > 21mmHg)








Visual acuity test, CDR (>0.7) and IOP
(≥23mmHg)
97% (for some form of
ocular abnormality)





CDR (≥0.6) and FDT perimetry (2 or
more missed locations at the































NCT (at least 1 eye IOP employees







CDR cup-disc ratio, FDT frequency doubling technology, NR not reported, NCT non-contact tonometry, IOP intraocular pressure, GCC ganglion cell complex,
RNFL retinal nerve fibre layer.
Fig. 1 Predictive performance of a screening test (73% sensitivity
and 96% specificity) when applied to an inception cohort of 50 years
of age with a glaucoma prevalence of 0.9%.
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fall substantially (Fig. 2). For each positive screening test result,
there will be a 57% chance of a false positive. This example
highlights the potential gains of targeting high-risk sub-popula-
tions, and the significant role genetic testing could play. While
genetic testing is not routine in the general population currently,
its affordability and applicability for multiple diseases make it a
likely possibility in the future. Targeted glaucoma screening of
people at high genetic risk of glaucoma is currently being
examined prospectively in a large Dutch cohort [26], which if
successful, could provide strong support for genotype-based
targeting screening for glaucoma in the future. It will be necessary
to determine the optimal testing strategy for people identified to
be at high risk (e.g., top decile of genetic risk and aged 50); this
may be community screening every 2 years until a glaucoma
diagnosis or until an upper age-limit when it is deemed unlikely to
develop vision loss due to glaucoma during remaining life. It will
also be necessary to demonstrate that genetic testing is feasible
and acceptable to the public, and to compare the innovative
screening strategy with current case detection in a prospective
randomised trial. Another major challenge is ensuring that any
prediction model is generalisable to diverse populations and
people of different ethnicities. To date, the majority of genome-
wide association studies have examined people of European
descent. While there appears to be good generalisability of
genetic loci between European and Asian populations, there may
be less overlap and correlation between European and African
populations [27, 28]. Future work in this field must aim to improve
genetic discovery in non-European ethnic groups to enable the
development and validation of prediction tools that can be
deployed equitably in the future.
Another potential tool to help enable effective population
screening for glaucoma is artificial intelligence-assisted image
interpretation. Deep learning techniques have enabled algorithms
that can classify optic disc images according to glaucoma risk and
the need for further examination for glaucoma [29]. In some cases,
the algorithm has been trained on images graded by multiple
experts, with the resultant algorithm outperforming any single
glaucoma expert in independent test sets [30]. While it may be
unlikely for the positive predictive value of such an algorithm to
be adequate when applied to the general population, it may be
that the algorithm is used to identify a subset of the population
that should be screened (rather than immediate referral). Similar
to Fig. 2, screening a sub-population enriched for glaucoma (as
detected by an optic disc image deep learning algorithm) may be
effective due to reduced false positives compared to screening the
general population. In addition, multimodal algorithms incorpor-
ating data and images on visual fields, IOP and optical coherence
tomography (OCT) may reach the point of adequate predictive
ability, even in a general population. Ultimately, approaches that
combine both genetic prediction and deep learning algorithms
may be developed.
Until effective population screening or targeted screening
programmes are achievable, opportunistic case finding through
General Ophthalmic Services (GOS) will remain the primary route
for identification of both symptomatic and asymptomatic
glaucoma in the UK. The GOS (commonly referred to as the
“sight test”) is provided by optometrists in community optical
practice, but with distinct differences in the contract across each
of the UK nations. It is provided as an NHS service for those
meeting a range of eligibility criteria; criteria pertinent to
glaucoma are as follows: having a diagnosis of glaucoma, aged
40 or over and either a parent, sibling or child that has been
diagnosed with glaucoma, advised by an ophthalmologist as
being at risk of glaucoma, aged 60 years and over [31]. The
exception for this being Scotland where a sight test is provided as
a universal NHS service to the whole population [32]. In addition,
the contracting arrangements in all the devolved nations allow
for the provision of supplementary services to improve the
quality of decision-making for onward referral to specialist
ophthalmic care [32–34], which include repeat measures and
referral refinement recommended by NICE [17]. In England, the
commissioning of these supplementary services are encouraged
and will be central to the models of care for glaucoma for the
Integrated Care Systems that are currently being established
[35, 36]. Despite these national differences, the GOS has an
established process and defined clinical and professional
standards. Greater public awareness of the service would not
only improve health literacy facilitating healthier choices, but also
improve case finding for a range of eye conditions including
glaucoma, in the population at risk.
It should be noted that the clinical and cost-effectiveness of
glaucoma screening depends on multiple factors that are specific to
the healthcare setting. Modelling studies in Finland [37] and China
[38] have suggested that population screening for glaucoma may be
cost-effective in those healthcare settings. However, it is acknowl-
edged that such models have uncertainty and can be sensitive to the
specificity of diagnostic tests and cost of screening [37]. Another
factor that is difficult to predict and can influence the effectiveness of
a screening programme is the attendance rate.
Glaucoma remains an important cause of avoidable sight loss in
England and Wales [39]. Effective population screening would enable
earlier diagnosis and prevention of irreversible vision loss. Major
advances in our ability to predict glaucoma risk using genetic markers,
increasingly affordable genotyping, and advances in machine learning
techniques all provide promise to enable innovative solutions for
effective glaucoma screening in the future.
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